Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CEPHALEXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CEPHALEXIN.
ARBLI vs CEPHALEXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting cell wall cross-linking, leading to cell lysis and death.
10 mg orally once daily.
Oral: 250-1000 mg every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Clinical Note
moderateCephalexin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Cephalexin."
Clinical Note
moderateCephalexin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Sulfisoxazole
0.5-1.2 hours in normal renal function; prolonged to 5-30 hours in severe renal impairment (CrCl <10 mL/min)
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The metabolism of Sulfisoxazole can be decreased when combined with Cephalexin."